AEG40730 HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 408130

CAS#: 1883545-50-3 (HCl)

Description: AEG40730 is a potent and selective IAP antagonist and a BIR-binding tetrapeptide. AEG40730 binds to cIAP1 and cIAP2, facilitates their autoubiquitination and proteosomal degradation, and causes a dramatic reduction in RIP1 ubiquitination. Treatment with nanomolar concentrations of AEG40730 resulted in the loss of both XIAP and c-IAP1 proteins, albeit with different kinetics.

Chemical Structure

img
AEG40730 HCl
CAS# 1883545-50-3 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 408130
Name: AEG40730 HCl
CAS#: 1883545-50-3 (HCl)
Chemical Formula: C52H70Cl2F6N8O8
Exact Mass: 0.00
Molecular Weight: 1,120.070
Elemental Analysis: C, 55.76; H, 6.30; Cl, 6.33; F, 10.18; N, 10.00; O, 11.43

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 934963-58-3 (free base)   1883545-50-3 (HCl)    

Synonym: AEG40730 HCl; AEG40730 dihydrochloride; AEG40730; AEG-40730; AEG 40730;

IUPAC/Chemical Name: (2S,2'S)-N,N'-((2S,2'S,3R,3'R)-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(1-oxo-1-((S)-2-((2,2,2-trifluoro-N-phenethylacetamido)methyl)pyrrolidin-1-yl)butane-3,2-diyl))bis(2-(methylamino)propanamide) dihydrochloride

InChi Key: CDGBXBVDDLOZGF-CLHBFWEXSA-N

InChi Code: InChI=1S/C52H68F6N8O8.2ClH/c1-35(59-5)45(67)61-43(47(69)65-27-17-23-41(65)33-63(49(71)51(53,54)55)29-25-39-19-11-9-12-20-39)37(3)73-31-15-7-8-16-32-74-38(4)44(62-46(68)36(2)60-6)48(70)66-28-18-24-42(66)34-64(50(72)52(56,57)58)30-26-40-21-13-10-14-22-40;;/h9-14,19-22,35-38,41-44,59-60H,17-18,23-34H2,1-6H3,(H,61,67)(H,62,68);2*1H/t35-,36-,37+,38+,41-,42-,43-,44-;;/m0../s1

SMILES Code: O=C(C(F)(F)F)N(CCC1=CC=CC=C1)C[C@H]2N(CCC2)C([C@@H](NC([C@@H](NC)C)=O)[C@@H](C)OCC#CC#CCO[C@@H]([C@H](NC([C@@H](NC)C)=O)C(N3[C@@H](CCC3)CN(C(C(F)(F)F)=O)CCC4=CC=CC=C4)=O)C)=O.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,120.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Faye MD, Beug ST, Graber TE, Earl N, Xiang X, Wild B, Langlois S, Michaud J, Cowan KN, Korneluk RG, Holcik M. IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene. 2015 Mar 19;34(12):1532-41. doi: 10.1038/onc.2014.90. Epub 2014 Apr 7. PMID: 24704827.


2: Cheung HH, Beug ST, St Jean M, Brewster A, Kelly NL, Wang S, Korneluk RG. Smac mimetic compounds potentiate interleukin-1beta-mediated cell death. J Biol Chem. 2010 Dec 24;285(52):40612-23. doi: 10.1074/jbc.M110.183616. Epub 2010 Oct 18. PMID: 20956527; PMCID: PMC3003360.


3: Cheung HH, Mahoney DJ, Lacasse EC, Korneluk RG. Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound. Cancer Res. 2009 Oct 1;69(19):7729-38. doi: 10.1158/0008-5472.CAN-09-1794. Epub 2009 Sep 22. PMID: 19773432.


4: Galbán S, Hwang C, Rumble JM, Oetjen KA, Wright CW, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Duckett CS. Cytoprotective effects of IAPs revealed by a small molecule antagonist. Biochem J. 2009 Feb 1;417(3):765-71. doi: 10.1042/BJ20081677. PMID: 18851715; PMCID: PMC2674510.


5: Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Barker PA. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008 Jun 20;30(6):689-700. doi: 10.1016/j.molcel.2008.05.014. PMID: 18570872.